Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


|Includes: Cytori Therapeutics Inc (CYTX)

A study was led by Momokazu Gotoh, MD, Ph.D., Professor and Chairman of the Department of Urology and Tokunori Yamamoto, MD, Ph.D., Associate Professor Department of Urology at Nagoya University Graduate School of Medicine demonstrate that stem and regenerative cells from a patient’s own fat tissue used to treat stress urinary incontinence (NYSE:SUI) demonstrate efficacy in severe cases. The cells in the study were processed using Cytori’s Celution® 800 System during the operative procedure.

The results, reported at the 7th Annual Meeting of the International Federation for Adipose Therapeutics and Science, suggest that the treatment is safe and feasible.  The adipose-derived stem and regenerative cells (ADRCs) were delivered via two distinct formulations. First, they were injected directly into the bladder sphincter with the goal of improving muscle contraction. Secondly, ADRCs were combined with the patient’s own fat tissue to create a cell-enriched bulking agent to improve closure upon sphincter contraction. They were five patients whose stress urinary incontinence  resulted from radical prostatectomy.

The follow-up examinations were thorough and frequent at two, four, eight, and 12 weeks. They were assessed for continence, intraurethral and leak point pressures (measures of urethral sphincter tone) and quality-of-life.  Imaging studies were made.     

Dr. Yamamoto comments confirmed that the transplanted cells stimulate new blood supply in the treated area, stabilize the transplanted tissue over time, and increase the urethral pressure in the majority of patients treated. “These early findings give hope to millions of patients suffering from untreatable incontinence and the resulting impact on their quality of life. Based on these results, we look forward to expanding the study to a larger population of patients.”

At twelve weeks following treatment, three of five patients showed improvement in leakage, urethral closure, and quality-of-life assessment. These three patients were diagnosed as having severe incontinence. Two of the five patients did not show improvement in these measures and were diagnosed as having very severe incontinence before treatment. It is likely that these very extreme cases, which represent the most difficult clinical challenge, could require multiple treatments.

Is this not great news for the 16 million new patients each year who lose ability to control their urinary flow in the United States alone. Besides the men who had prostatectomy, stress incontinence is common in women, even more common than in men, as it results from childbirth, menopause and natural aging.  

Indeed it is great news for the sufferers from urinary incontinence, the physicians who have yet to find a safe satisfactory answer and the millions of patients who suffer the painful embarrassing condition.

Disclosure: No Positions